SLC16A1 and neoplasm: In light of this, deletion of MCT1 specifically on Tregs was shown to slow tumor growth and synergize with anti–PD-1 therapy, suggesting that pharmacologic inhibition of MCT1 may play a dual role, both to inhibit lactate secretion by tumor cells and to impair immunosuppressive Tregs (16).